18F-FET PET imaging for pituitary adenomas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-centre pilot will enroll up to 20 adults with newly diagnosed or residual/recurrent pituitary adenomas who previously underwent 11C-methionine PET as part of routine care. Enrolled participants will receive an 18F-fluoroethyl-tyrosine (FET) PET scan at Cambridge University Hospitals. Quantitative and qualitative image analyses will compare lesion localization and uptake patterns between prior Met-PET and the new FET-PET scans. The study aims to determine whether FET-PET provides comparable imaging information to Met-PET for surgical or radiotherapy planning.

Why it matters

Who can join: the full rules

Inclusion criteria

* Participant is willing and able to give informed consent for participation in the study
* Male or female, age 18 or above
* Presence of pituitary adenoma suspected on the basis of clinical/biochemical and/or radiological findings
* Previous 11C-Met-PET/CT

Exclusion criteria

* Inability to give informed consent
* Pregnancy or suspected pregnancy
* Inability to lie supine for 30-60 minutes
* Patient body habitus above scanner dimensions
* Known allergy to intravenous radiographic contrast agents

Where it's running

• Cambridge University Hospitals
  Cambridge, Cambridgeshire, United Kingdom Recruiting

Study contacts

• Principal investigator: Mark Gurnell, MD, PhD — Cambridge University Hospitals NHS Foundation Trust
• Study coordinator: James MacFarlane
• Email: jm2267@medschl.cam.ac.uk
• Phone: 01223 250882

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Panitumumab-IRDye800 for guiding brain tumor surgery

  A tiny dose of panitumumab-IRDye800 is tested to see if it helps visualize brain tumors during surgery in adults.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07493447

• Fluid-based PET imaging to locate ACTH-secreting pituitary adenomas in Cushing disease

  This study tests whether FET PET/CT scanning can accurately locate ACTH-secreting pituitary adenomas in adults with Cushing disease who are planning pituitary surgery.

  Recruiting Early Phase 1 Mayo Clinic · Rochester, Minnesota · NCT07460232

• FET-PET/MRI to locate small hormone-producing pituitary adenomas

  This trial tests whether a special PET/MRI scan called FET-PET/MRI can find small hormone-producing pituitary adenomas in adults whose standard MRI is negative or unclear.

  Recruiting Phase 1 Mayo Clinic · Jacksonville, Florida · NCT07456878

• Intraoperative contrast-enhanced ultrasound to locate pituitary adenomas in Cushing's disease

  This pilot tests whether using contrast-enhanced ultrasound during transsphenoidal surgery helps surgeons find and remove pituitary adenomas in people with Cushing's disease.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07335315

• Anti-fog suction device during endoscopic pituitary surgery

  This trial tests whether an anti-fog suction device helps keep the view clear during pituitary tumor surgery and whether it lowers brain-fluid infection risk compared with the usual water-squirting method.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07316101

• Long-term experience with pituitary tumors

  This study looks at the experiences of over 1600 patients who had surgery for pituitary tumors to see what factors might affect their recovery and overall health.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, IT · NCT06973824

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.